Japan Tobacco Inc.

Takaki Maeba

Masayuki Kotoku

Hiroshi Yamanaka

Masahiro Yokota

Makoto Shiozaki

Koichi Suzawa

Dai Motoda

Shintaro Hirashima

Noriyoshi Seki

Ritsuki Masuo

Nobutaka Yamaoka

Katsuya Maeda

Kazayuki Hirata

Shingo Obika

Kazuyuki Hirata

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof: wherein each symbol means the same as that described in the specification.

Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof

A compound of formula [I-W]: wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

Amide compound and medicinal use thereof

Growing community of inventors

Osaka, Japan

Takaki Maeba